Loading stock data…
SHC
$15.50-0.06 (-0.39%)
Market ClosedLast close May 1
Sotera Health Company provides sterilization solutions, lab testing, and advisory services for the healthcare industry in the United States, Canada, Europe, and internationally.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Sotera Health Company in the Healthcare sector is trading at $15.50. The stock is currently 22% below its 52-week high of $19.85, remaining 2.6% below its 200-day moving average. Technical signals show neutral RSI of 47 and bearish MACD signal, explaining why SHC maintains its current current market pressure. The Whystock Score of 50/100 suggests a balanced risk-reward profile.
Ecosystem Influences
Neutral momentum (RSI 47) — price action in range
Long-term trend bearish (Price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Loading Financials...
Peer Comparison
JNJUNHPFE
Whystock Valuation Model
Whystock fair value is estimated using a trailing P/E model adjusted for return on equity: Fair P/E = 18 + (ROE × 20). Fair Value = (Current Price ÷ Trailing P/E) × Fair P/E. A base P/E of 18 represents a typical market multiple, scaled upward for companies that earn high returns on equity. The result is a theoretical "normalised" price — not a price target or investment advice. Large deviations are common for high-growth or loss-making companies.
Current Price$15.50
Potential Downside
66.9%
Whystock Fair Value$5.13
Price
UndervaluedFair ValueOvervalued
Simplified model based on P/E and ROE. Not a substitute for full valuation analysis. Data may be delayed. See our Terms.
Analyst Consensus8 analysts
Buy
Mean target$20.50+32.3%
Range$16.00 – $24.00
Fundamentals
Sotera Health Company provides sterilization solutions, lab testing, and advisory services for the healthcare industry in the United States, Canada, Europe, and internationally. The company operates through three segments: Sterigenics, Nordion, and N...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$4.37B
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
56.78
Beta
High-beta play. Expect amplified moves vs. the broad market.
1.88
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
3.96%
Volume
Today's trading volume
3.50M
Recent News
3 Healthcare Stocks That Fall Short
From novel pharmaceuticals to telemedicine, most healthcare companies are on a mission to drive better patient outcomes. But financial performance has lagged recently as players offloaded surplus COVID inventories in 2023 and 2024, a headwind for overall demand. The result? Over the past six months, the industry’s return was flat while the S&P 500 climbed by 5%.
Sotera Health (SHC) Q3 2024 Earnings Transcript
Please refer to Sotera Health's SEC filings and the forward-looking statement slide at the beginning of the presentation for a description of these risks and uncertainties. Please note that during the discussion today, the company will present both GAAP and non-GAAP financial measures, including adjusted EBITDA, adjusted EBITDA margin, segment income margin, adjusted net income, adjusted EPS and net leverage ratio in addition to constant currency comparisons. Michael Petras: Good morning, everyone, and thank you for joining Sotera Health's Third Quarter 2024 Earnings Call.
3 Profitable Stocks That Concern Us
Not all profitable companies are built to last - some rely on outdated models or unsustainable advantages. Just because a business is in the green today doesn’t mean it will thrive tomorrow.
OKLO's Isotope Push Could Support Long-Term Growth Opportunity
OKLO's isotope strategy aims to fix fragile global supply by converting nuclear waste into high-value materials for medicine, industry and security.
Sotera Health Company (SHC): Buy, Sell, or Hold Post Q4 Earnings?
Although the S&P 500 is down 2.1% over the past six months, Sotera Health Company’s stock price has fallen further to $14.85, losing shareholders 7.2% of their capital. This might have investors contemplating their next move.